valine and nelfinavir
valine has been researched along with nelfinavir in 6 studies
Research
Studies (6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Cammack, N; Chirn, GW; Craig, C; Dissanayeke, S; Duncan, IB; Gilbert, S; Moffatt, A; Race, E; Rose, J; Sheldon, J; Whittaker, L | 1 |
| Freire, E; Luque, I; Todd, MJ; Velázquez-Campoy, A | 1 |
| Blum, LE; Clemente, JC; Dunn, BM; Goodenow, MM; Hemrajani, R | 1 |
| Birnböck, H; Götschi, A; Lavé, T; Pähler, A; Ramp, T | 1 |
| Gocke, E; Grimm, HP; Lavé, T; Müller, L; Paehler, A | 1 |
Other Studies
6 other study(ies) available for valine and nelfinavir
| Article | Year |
|---|---|
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.
Topics: Amino Acid Substitution; Carbamates; Clinical Trials as Topic; Databases, Factual; DNA, Viral; Furans; Genetic Linkage; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Methionine; Nelfinavir; Phenotype; Polymerase Chain Reaction; Ritonavir; Saquinavir; Sulfonamides; Valine | 1998 |
Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.
Topics: Amino Acid Substitution; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Drug Resistance, Microbial; Entropy; Enzyme Stability; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Mutagenesis, Site-Directed; Nelfinavir; Phenylalanine; Protons; Ritonavir; Saquinavir; Thermodynamics; Valine | 2000 |
Protease inhibitor trials moving to next phase.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication | 1995 |
Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
Topics: Alanine; Anti-HIV Agents; Asparagine; Aspartic Acid; Binding Sites; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoleucine; Kinetics; Methionine; Mutagenesis, Site-Directed; Nelfinavir; Ritonavir; Valine | 2003 |
In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human.
Topics: Alkylating Agents; Animals; Dose-Response Relationship, Drug; Drug Contamination; Ethyl Methanesulfonate; Half-Life; Hemoglobins; HIV Protease Inhibitors; Humans; Macaca fascicularis; Male; Mice; Microsomes, Liver; Mutagens; Nelfinavir; Rats; Risk Assessment; Species Specificity; Tablets; Valine | 2009 |
Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients.
Topics: Alkylating Agents; Animals; Area Under Curve; Computer Simulation; Dose-Response Relationship, Drug; Drug Contamination; Ethyl Methanesulfonate; Hemoglobins; HIV Protease Inhibitors; Humans; In Vitro Techniques; Macaca fascicularis; Mice; Microsomes, Liver; Models, Biological; Mutagens; Nelfinavir; Rats; Risk Assessment; Species Specificity; Valine | 2009 |